RU2015129366A - Способы и композиции, относящиеся к лечению злокачественной опухоли - Google Patents

Способы и композиции, относящиеся к лечению злокачественной опухоли Download PDF

Info

Publication number
RU2015129366A
RU2015129366A RU2015129366A RU2015129366A RU2015129366A RU 2015129366 A RU2015129366 A RU 2015129366A RU 2015129366 A RU2015129366 A RU 2015129366A RU 2015129366 A RU2015129366 A RU 2015129366A RU 2015129366 A RU2015129366 A RU 2015129366A
Authority
RU
Russia
Prior art keywords
isc
malignant tumor
cetuximab
treating
prodrug
Prior art date
Application number
RU2015129366A
Other languages
English (en)
Russian (ru)
Inventor
Джошуа Е. Аллен
Уафик С. ЭЛЬ-ДЭЙРИ
Арун К. ШАРМА
Шанту Г. АМИН
Розалин ИРБИ
Original Assignee
Зэ Пэнн Стэйт Рисерч Фандэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зэ Пэнн Стэйт Рисерч Фандэйшн filed Critical Зэ Пэнн Стэйт Рисерч Фандэйшн
Publication of RU2015129366A publication Critical patent/RU2015129366A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015129366A 2012-12-20 2013-12-20 Способы и композиции, относящиеся к лечению злокачественной опухоли RU2015129366A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740126P 2012-12-20 2012-12-20
US61/740,126 2012-12-20
PCT/US2013/076869 WO2014100565A1 (en) 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer

Publications (1)

Publication Number Publication Date
RU2015129366A true RU2015129366A (ru) 2017-01-25

Family

ID=49950064

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015129366A RU2015129366A (ru) 2012-12-20 2013-12-20 Способы и композиции, относящиеся к лечению злокачественной опухоли

Country Status (10)

Country Link
US (1) US20150328310A1 (enExample)
EP (1) EP2934583A1 (enExample)
JP (1) JP2016503063A (enExample)
KR (1) KR20150099588A (enExample)
CN (1) CN105007940B (enExample)
AU (1) AU2013361164A1 (enExample)
CA (1) CA2894547A1 (enExample)
RU (1) RU2015129366A (enExample)
SG (1) SG11201504779YA (enExample)
WO (1) WO2014100565A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2008128189A1 (en) * 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods

Also Published As

Publication number Publication date
KR20150099588A (ko) 2015-08-31
CN105007940A (zh) 2015-10-28
AU2013361164A1 (en) 2015-07-02
WO2014100565A1 (en) 2014-06-26
EP2934583A1 (en) 2015-10-28
CA2894547A1 (en) 2014-06-26
SG11201504779YA (en) 2015-07-30
US20150328310A1 (en) 2015-11-19
CN105007940B (zh) 2017-08-25
JP2016503063A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
JP7562296B2 (ja) がんの処置のための併用治療
RU2015106524A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf
JP2022017295A (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
JP2016535756A5 (enExample)
TR201807411T4 (tr) DNA-PK inhibitörleri.
ES2886107T3 (es) Antineoplásico
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
Del Corso et al. Current trends in oral cancer: A review
JP2015536964A5 (enExample)
JP2021502345A (ja) 抗がん剤
JP2014132009A5 (enExample)
Velenik et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
HRP20201737T1 (hr) Metoda za liječenje tumora, farmaceutski sastav i pribor za lijekove
JP2016533366A5 (enExample)
Singh et al. Profiling pathway‐specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR‐ErbB2 signaling with lapatinib
JP2016529285A5 (enExample)
RU2017119066A (ru) Композии апилимода и способы их применения в лечении колоректального рака
JP2019515889A (ja) （１ｓ，４ｓ）−４−（２−（（（３ｓ，４ｒ）−３−フルオロテトラヒドロ−２ｈ−ピラン−４−イル）アミノ）−８−（（２，４，６−トリクロロフェニル）アミノ）−９ｈ−プリン−９−イル）−１−メチルクロロヘキサン−１−カルボキサミドの固体形態及びその使用方法
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
JP2014530181A5 (enExample)
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
KR20160006669A (ko) 5-브로모-인디루빈
JP2016503063A5 (enExample)
TWI837231B (zh) 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180710